About Akebia Therapeutics, Inc.
https://www.akebia.comAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
CEO
John P. Butler MBA
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 103
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:18.8M
Value:$25.94M
VANGUARD GROUP INC
Shares:15.55M
Value:$21.46M
STATE STREET CORP
Shares:11.84M
Value:$16.35M
Summary
Showing Top 3 of 212
About Akebia Therapeutics, Inc.
https://www.akebia.comAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $58.77M ▼ | $44.62M ▲ | $540K ▲ | 0.92% ▲ | $0 ▲ | $6.22M ▼ |
| Q2-2025 | $62.47M ▲ | $38.46M ▲ | $247K ▼ | 0.4% ▼ | $0 ▼ | $7.4M ▼ |
| Q1-2025 | $57.34M ▲ | $36.2M ▼ | $6.11M ▲ | 10.66% ▲ | $0.03 ▲ | $14.2M ▲ |
| Q4-2024 | $46.5M ▲ | $40.44M ▲ | $-22.8M ▼ | -49.04% ▲ | $-0.1 ▼ | $-6.58M ▼ |
| Q3-2024 | $37.43M | $35.77M | $-20.04M | -53.54% | $-0.1 | $-4M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $166.44M ▲ | $364.15M ▲ | $322.56M ▲ | $41.59M ▲ |
| Q2-2025 | $137.31M ▲ | $345.6M ▲ | $316.37M ▲ | $29.22M ▲ |
| Q1-2025 | $113.37M ▲ | $310.19M ▲ | $285.6M ▲ | $24.58M ▲ |
| Q4-2024 | $51.87M ▲ | $220.67M ▲ | $269.86M ▲ | $-49.19M ▲ |
| Q3-2024 | $34.02M | $207.14M | $257.54M | $-50.4M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $540K ▲ | $28.11M ▲ | $-77K ▲ | $1.11M ▼ | $29.14M ▲ | $28.03M ▲ |
| Q2-2025 | $247K ▼ | $22.34M ▲ | $-126K ▼ | $1.72M ▼ | $23.93M ▼ | $22.22M ▲ |
| Q1-2025 | $6.11M ▲ | $-13.59M ▼ | $154K ▲ | $74.94M ▲ | $61.51M ▲ | $-13.61M ▼ |
| Q4-2024 | $-22.8M ▼ | $-4.47M ▲ | $-2K | $22.32M ▲ | $17.85M ▲ | $-4.47M ▲ |
| Q3-2024 | $-20.04M | $-6.7M | $-2K | $1.22M | $-5.47M | $-6.7M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License Collaboration And Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $90.00M ▲ | $60.00M ▼ | $60.00M ▲ | $60.00M ▲ |
CEO
John P. Butler MBA
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 103
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:18.8M
Value:$25.94M
VANGUARD GROUP INC
Shares:15.55M
Value:$21.46M
STATE STREET CORP
Shares:11.84M
Value:$16.35M
Summary
Showing Top 3 of 212